Pharma sales bring rare cheer as markets batter Bayer again

30 July 2019

The troubles of the Crop Science division overshadowed the more encouraging figures in Pharmaceuticals in the latest quarterly financial results at German life sciences group Bayer (BAYN: DE).

Shares in the company were 4% down as trading entered its final third on Tuesday, with a major factor in this likely to be Bayer admitting that the group’s targets for 2019 were now looking ‘increasingly ambitious,’ including the group sales estimate of 46 billion euros.

Another worry was the latest update on US lawsuits in connection with the Roundup (glyphosate) product that the group acquired in its acquisition with Monsanto. There are now around 18,400 plaintiffs, though Bayer continues to claim that it has a robust defense against the allegations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK